Want to see PL:MAB full AI Analyst Report?

Mabion SA (MAB) AI Stock Analysis

0 Followers

Top Page

Mabion SA

(MAB)

Select Model

Rating:41Neutral

Price Target:

zł9.00

▲(22.12% Upside)

Action:N/A

Date:09/16/25

The overall score is driven by weak financial performance marked by contracting revenues, negative profitability, and declining returns, with only partial offset from an improved cash position and low leverage. The lack of technical indicator data further drags the score, while valuation is undermined by sustained negative P/E and no dividend. Absent earnings call or corporate event data, the outlook remains subdued.

Positive Factors

Operational Efficiency

Maintaining a positive EBITDA margin indicates operational efficiency, allowing the company to cover its operating expenses and potentially improve profitability over time.

Negative Factors

Declining Gross Profit Margin

A declining gross profit margin indicates rising costs or pricing pressures, which could erode profitability and limit resources available for growth initiatives.

Read all positive and negative factors

Positive Factors

Negative Factors

Operational Efficiency

Maintaining a positive EBITDA margin indicates operational efficiency, allowing the company to cover its operating expenses and potentially improve profitability over time.

Read all positive factors

Mabion SA (MAB) vs. SPDR S&P 500 ETF (SPY)

Market Cap

zł120.57M

Dividend YieldN/A

Average Volume (3M)38.65K

Price to Earnings (P/E)―

Beta (1Y)0.64

Revenue Growth-53.36%

EPS Growth-45.92%

CountryPL

Employees202

SectorHealthcare

Sector Strength45

IndustryBiotechnology

Share Statistics

EPS (TTM)-3.53

Shares Outstanding16,162,327

10 Day Avg. Volume25,807

30 Day Avg. Volume38,648

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)2.31

Price to Sales (P/S)7.16

P/FCF Ratio-2.66

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-1.6

Revenue Forecast (FY)zł60.00M

Mabion SA Business Overview & Revenue Model

Company Description

Mabion S.A. is a Polish biopharmaceutical firm dedicated to pioneering the development of biological drugs, primarily leveraging monoclonal antibody technology. The company oversees the full spectrum from research and development to the manufactur...

How the Company Makes Money

Mabion generates revenue primarily through the development and commercialization of its biopharmaceutical products. The company earns money by selling its biosimilars to healthcare providers and pharmaceutical companies, often under licensing agre...

Mabion SA Financial Statement Overview

Summary

Mabion SA faces severe financial headwinds: revenues declined sharply, profit margins are negative, and the company moved from profit to operational losses in 2024. The exception is strong free cash flow generation for the year, reflecting improved liquidity and low leverage, but these improvements are outweighed by top-line contraction and negative returns for shareholders.

Income Statement

Negative

Balance Sheet

Neutral

Cash Flow

Positive

Breakdown	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	15.76M	69.02M	151.68M	163.98M	56.87M
Gross Profit	-17.41M	41.15M	114.58M	65.99M	28.18M
EBITDA	-43.66M	10.20M	58.31M	29.63M	118.00K
Net Income	-62.61M	-6.33M	41.27M	23.19M	1.90M
Balance Sheet
Total Assets	110.43M	159.47M	208.25M	186.18M	184.24M
Cash, Cash Equivalents and Short-Term Investments	6.37M	38.45M	47.82M	53.64M	48.71M
Total Debt	12.69M	4.61M	35.83M	7.28M	20.36M
Total Liabilities	55.08M	48.03M	90.48M	109.67M	130.92M
Stockholders Equity	48.83M	111.44M	117.78M	76.51M	53.31M
Cash Flow
Free Cash Flow	-42.48M	26.28M	-40.33M	22.11M	-64.53M
Operating Cash Flow	-41.59M	39.86M	-2.33M	38.84M	-32.91M
Investing Cash Flow	-795.00K	-12.29M	-37.98M	-16.06M	-31.28M
Financing Cash Flow	10.31M	-36.95M	34.49M	-17.84M	110.50M

Mabion SA Technical Analysis

Technical Analysis Sentiment

Positive

Last Price7.37

Price Trends

50DMA

7.43

Positive

100DMA

7.79

Negative

200DMA

7.84

Negative

Market Momentum

MACD

<0.01

Negative

RSI

54.87

Neutral

STOCH

71.11

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PL:MAB, the sentiment is Positive. The current price of 7.37 is below the 20-day moving average (MA) of 7.46, below the 50-day MA of 7.43, and below the 200-day MA of 7.84, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.87 is Neutral, neither overbought nor oversold. The STOCH value of 71.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PL:MAB.

Mabion SA Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MAB	41 Neutral	zł120.57M	-2.11	-95.68%	―	-53.36%	-45.92%
RVU	37 Underperform	zł340.79M	-3.77	-135.46%	―	-15.04%	24.48%
CTX	34 Underperform	zł471.42M	-9.61	-150.18%	―	-82.90%	2.18%

* Healthcare Sector Average

Performance Comparison

PL:MAB

Mabion SA

7.57

-1.97

-20.65%

PL:RVU

Ryvu Therapeutics SA

16.02

-14.93

-48.24%

PL:SCP

Scope Fluidics SA

135.60

-19.40

-12.52%

PL:SVE

Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.

3.09

-1.81

-36.94%

PL:CTX

Captor Therapeutics SA

70.70

30.20

74.57%

PL:MOC

OncoArendi Therapeutics SA

6.05

-1.79

-22.83%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 16, 2025